S1P Receptor Modulators With Subtype-Selective S1P1 Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions mediated by sphingosine-1-phosphate receptor activation lack effective modulators that can selectively target specific receptor subtypes, leading to inadequate therapeutic outcomes.
Innovation Solution
Development of compounds that modulate S1P1 receptors, including both orthosteric and allosteric agonists, which selectively activate the S1P1 subtype and optionally other subtypes like S1P5, providing targeted signal transduction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for conditions mediated by sphingosine-1-phosphate receptor activation are used, then therapeutic outcomes are achieved, but selectivity for specific receptor subtypes is insufficient
Solution Approach 1:
The patent segments the broad S1P receptor modulation into subtype-specific targeting. By designing compounds that selectively activate S1P1 or S1P5 receptors while sparing other subtypes, the invention divides the therapeutic effect into precise, controllable components. This segmentation allows clinicians to target specific pathological pathways without affecting other S1P-mediated physiological processes, thereby improving therapeutic reliability while achieving high receptor subtype selectivity.
Solution Approach 2:
The patent applies local quality by creating compounds with differentiated binding characteristics for different receptor subtypes. The molecular structure is optimized to exhibit high affinity and selectivity for specific S1P receptor subtypes (S1P1 or S1P5) while maintaining low affinity for others. This localized specificity ensures that therapeutic effects are concentrated at the desired target site without off-target effects, resolving the contradiction between therapeutic reliability and receptor subtype selectivity.
2Reliability
If broad S1P receptor modulation is used, then therapeutic effects are achieved, but side effects increase due to lack of selectivity
Solution Approach 1:
The patent extracts the desired therapeutic effect from the broader S1P receptor modulation by isolating activation of specific subtypes (S1P1 or S1P5). By taking out only the necessary receptor subtype activation required for therapeutic effect and eliminating engagement with other subtypes, the invention achieves potent therapeutic effects while minimizing side effects that would result from non-selective broad modulation.
Solution Approach 2:
The patent converts the potential harm of broad receptor modulation into benefit by using selective subtype activation. Instead of accepting non-selective activation as an unavoidable consequence of achieving therapeutic effects, the invention transforms the challenge into an advantage by designing compounds that exploit the structural and functional differences between S1P receptor subtypes. This selective approach converts what would be harmful off-target effects into a benefit of enhanced therapeutic index through improved selectivity.
Data Source
AI summary
Compounds are provided having the structure of Formula (I): (Formula (I)) or a pharmaceutically acceptable salt, homolog, hydrate or solvate thereof, wherein R is as defined herein. Such compounds serve as modulators of the sphingosine-1-phosphate receptor, and have utility for treatment of a malcondition for which activation of this receptor is medically indicated.